DE60224383D1 - Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen - Google Patents

Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen

Info

Publication number
DE60224383D1
DE60224383D1 DE60224383T DE60224383T DE60224383D1 DE 60224383 D1 DE60224383 D1 DE 60224383D1 DE 60224383 T DE60224383 T DE 60224383T DE 60224383 T DE60224383 T DE 60224383T DE 60224383 D1 DE60224383 D1 DE 60224383D1
Authority
DE
Germany
Prior art keywords
disease
yeast
protein
procedure
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224383T
Other languages
English (en)
Other versions
DE60224383T2 (de
DE60224383T3 (de
Inventor
Susan Lindquist
Sylvia Krobitsch
Tiago Outeiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23026039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60224383(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Chicago filed Critical University of Chicago
Publication of DE60224383D1 publication Critical patent/DE60224383D1/de
Publication of DE60224383T2 publication Critical patent/DE60224383T2/de
Application granted granted Critical
Publication of DE60224383T3 publication Critical patent/DE60224383T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
DE60224383T 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittel die proteinfaltung beeinflussen Expired - Lifetime DE60224383T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26915701P 2001-02-15 2001-02-15
US269157P 2001-02-15
PCT/US2002/004632 WO2002065136A2 (en) 2001-02-15 2002-02-15 Yeast screens for agents affecting protein folding
EP02718994A EP1392849B2 (de) 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittel die proteinfaltung beeinflussen

Publications (3)

Publication Number Publication Date
DE60224383D1 true DE60224383D1 (de) 2008-02-14
DE60224383T2 DE60224383T2 (de) 2009-01-08
DE60224383T3 DE60224383T3 (de) 2012-06-28

Family

ID=23026039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224383T Expired - Lifetime DE60224383T3 (de) 2001-02-15 2002-02-15 Verfahren zum nachweis in hefe für mittel die proteinfaltung beeinflussen

Country Status (8)

Country Link
US (7) US7045290B2 (de)
EP (2) EP1392849B2 (de)
JP (2) JP4344138B2 (de)
AT (2) ATE382704T1 (de)
AU (3) AU2002250102B2 (de)
CA (1) CA2438661C (de)
DE (1) DE60224383T3 (de)
WO (1) WO2002065136A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
DE60224383T3 (de) * 2001-02-15 2012-06-28 The University Of Chicago Verfahren zum nachweis in hefe für mittel die proteinfaltung beeinflussen
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
EP1575510A4 (de) * 2002-08-07 2007-12-26 Univ Delaware Zusammensetzungen und verfahren zur behandlung von krankheiten mit protein-fehlanordnung und aggregation
FR2846009B1 (fr) * 2002-10-18 2007-10-12 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
FR2846008B1 (fr) * 2002-10-18 2006-06-02 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
JP2007521792A (ja) * 2003-04-16 2007-08-09 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 異常に切断されたタンパク質を異所性発現する酵母、およびこの用途
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
CA2525784C (en) 2003-05-16 2019-04-09 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
DK1644505T3 (da) * 2003-07-11 2008-08-18 Remynd Nv Gærmodel for amyloidogen proteintoksicitet
US7452670B2 (en) 2003-12-04 2008-11-18 University Of Washington Methods of identifying agents that diminish cellular toxicity associated with an α-synuclein polypeptide of Parkinson's disease in yeast
US8192986B2 (en) * 2004-05-05 2012-06-05 Whitehead Institute For Biomedical Research Compositions and methods for treatment of protein misfolding diseases
CA2566731C (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
CA2568644C (en) * 2004-06-03 2015-11-24 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
NZ584773A (en) 2004-09-17 2012-07-27 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US7504227B2 (en) * 2004-10-20 2009-03-17 University Of Washington Drug targets for the treatment of neurodegenerative disorders
US7618793B2 (en) * 2004-10-20 2009-11-17 The Regents Of The University Of Washington Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide
AU2005323173A1 (en) * 2004-12-01 2006-07-13 The Curators Of The University Of Missouri Modulator of alpha-synuclein toxicity
EP1888095A4 (de) 2005-05-13 2009-08-26 Whitehead Biomedical Inst Modulatoren der alpha-synuclein-toxizität
US7368258B1 (en) * 2005-06-06 2008-05-06 University Of Maryland, Baltimore County Devices and methods for profiling enzyme substrates
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
EP2007373A4 (de) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc Hemmung der alpha-synuclein-toxizität
GB0610792D0 (en) * 2006-06-02 2006-07-12 Remynd Nv Methods and tools for the screening of factors affecting protein misfolding
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
US8975063B2 (en) 2006-10-19 2015-03-10 California Institute Of Technology Compositions and methods for producing benzylisoquinoline alkaloids
US8323952B2 (en) * 2007-12-13 2012-12-04 Archer Daniels Midland Company Alcoholic xylose fermentation at high temperatures by the thermotolerant yeast Hansenula polymorpha
WO2009086306A1 (en) 2007-12-21 2009-07-09 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
EP2262895B1 (de) 2008-02-15 2013-08-14 Whitehead Institute For Biomedical Research Hefezellen mit expression des tar-dna-bindungsproteins 43 und verwendungen dafür
ES2418459B1 (es) * 2008-10-09 2014-08-12 Universitat Autònoma De Barcelona Relacionando agregación proteica con supervivencia de levadura
US8865411B2 (en) 2009-03-26 2014-10-21 National Institutes Of Health (Nih) Methods of identifying modulators of TDP-43 mediated cellular toxicity
EP2524040B1 (de) * 2010-01-12 2017-03-15 The Whitehead Institute for Biomedical Research Hefezellen zur expression von amyloid-beta und verwendungen davon
CN101858910B (zh) * 2010-03-25 2013-03-27 辽宁大学 一种在蛋白质水平精确定量检测抗朊病毒药物作用效果的方法
WO2013179144A2 (en) * 2012-06-01 2013-12-05 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
US10642376B2 (en) 2012-11-28 2020-05-05 Intel Corporation Multi-function stylus with sensor controller
EP2970999A2 (de) 2013-03-15 2016-01-20 The Board Of Trustees Of The University Of the Leland Stanford Junior University Benzylisochinolin-alkaloide (bia) produzierende mikroben sowie verfahren zur herstellung und verwendung davon
US11047848B2 (en) 2013-03-15 2021-06-29 Whitehead Institute For Biomedical Research Cellular discovery platform for neurodegenerative diseases
CN112410379A (zh) 2013-11-04 2021-02-26 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)前体的微生物以及制备和使用所述前体的方法
CH709681A1 (de) 2014-05-21 2015-11-30 Explo Engineering Ag Pulsdetonationsantrieb.
EP3155003B9 (de) 2014-06-13 2020-12-30 Whitehead Institute for Biomedical Research Amyloid-beta-expression-konstrukte und verwendungen davon
JP2017522886A (ja) * 2014-07-29 2017-08-17 ニューリミューン ホールディング エイジー ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP6824158B2 (ja) * 2014-09-12 2021-02-03 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ アポリポタンパク質ｅを発現する細胞及びその使用
CN107614688B (zh) 2015-05-04 2023-02-28 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)前体的微生物及其制备和使用方法
GB2555044B (en) 2015-05-08 2021-03-17 Univ Leland Stanford Junior Methods of producing epimerases and benzylisoquinoline alkaloids
EP3423158B1 (de) * 2016-02-24 2023-11-15 The Rockefeller University Embryonalzellbasierte therapeutische kandidatenscreening-systeme, modelle für die huntington-krankheit und verwendungen davon
MX2019009117A (es) 2017-02-17 2019-09-13 Bristol Myers Squibb Co Anticuerpos anti alfa-sinucleina y usos de los mismos.
WO2019028390A1 (en) 2017-08-03 2019-02-07 Antheia, Inc. ALKALOID BENZYLISOQUINOLEIN GENETICALLY MODIFIED EPIMERASES AND METHODS FOR PRODUCING BENZYLISOQUINOLINE ALKALOIDS
US10550550B2 (en) * 2017-09-13 2020-02-04 Dominic P. Ismert Modular two-part sillcock
US10649550B2 (en) 2018-06-26 2020-05-12 Intel Corporation Predictive detection of user intent for stylus use
WO2023284782A1 (zh) * 2021-07-14 2023-01-19 复旦大学 筛选用于治疗或预防mHTT相关的神经退行性疾病的化合物的方法，靶蛋白，以及化合物
WO2023137286A1 (en) * 2022-01-12 2023-07-20 Arizona Board Of Regents On Behalf Of Arizona State University Methods and related aspects of quantifying protein stability and misfolding
CN114990049B (zh) * 2022-04-26 2024-01-16 鼎康(武汉)生物医药有限公司 一种同时调节细胞表达产物的糖型和电荷异质性的方法
DE202022107272U1 (de) 2022-12-28 2023-01-30 Centurion University of Technology and Management Ein System zur Analyse der Infektion mit Pseudomonas Syringae durch gezielte Ansprache von Cochaperonen, die eine J-Domäne enthalten

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
US5547841A (en) * 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
JPH05502368A (ja) * 1989-09-18 1993-04-28 サイオス　ノバ　インコーポレイテッド アミロイド沈着物の測定法および試薬
GB8921791D0 (en) 1989-09-27 1989-11-08 Imp Cancer Res Tech Disease gene
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
DE4204650C1 (de) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
KR940021073A (ko) * 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
CA2157774A1 (en) 1993-04-07 1994-10-13 Christopher John Marshall Methods for screening of substances for therapeutic activity and yeast for use therein
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US6093549A (en) * 1995-11-09 2000-07-25 The Johns Hopkins University Huntingtin-associated protein-related assays
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
WO1999006545A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
US5952217A (en) * 1997-09-23 1999-09-14 Bristol-Myers Squibb Company Recombinant yeast cell and assay using same
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US20010006793A1 (en) * 1998-03-20 2001-07-05 Mary-Ann Bjornsti Modulators of eukaryotic caspases
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
NZ515956A (en) 1999-07-02 2004-04-30 Janssen Pharmaceutica Nv Transgenic animals as models for neurodegenerative disease
EP1204674A4 (de) * 1999-07-27 2005-06-01 Abgenix Inc Methoden und verbindungen zur verhinderung von polypeptid-ansammlungen im zusammenhang mit neurologischen störungen
US6420122B1 (en) * 1999-09-27 2002-07-16 Massachusetts Institute Of Technology Methods of screening for agents that inhibit aggregation of polypeptides
MXPA02007796A (es) * 2000-02-21 2003-12-08 Pharmexa As Metodo novedoso para la disminucion de cuerpos amiloides.
IT1317922B1 (it) 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe Metodo per identificare in vivo epitopi intracellulari.
DE60224383T3 (de) * 2001-02-15 2012-06-28 The University Of Chicago Verfahren zum nachweis in hefe für mittel die proteinfaltung beeinflussen
GB0104685D0 (en) * 2001-02-26 2001-04-11 Leuven K U Res & Dev Tau-opathy model
US20030022243A1 (en) 2001-06-20 2003-01-30 Les Kondejewski Protein aggregation assays and uses thereof
DK1644505T3 (da) 2003-07-11 2008-08-18 Remynd Nv Gærmodel for amyloidogen proteintoksicitet

Also Published As

Publication number Publication date
US8039209B2 (en) 2011-10-18
US20130005608A1 (en) 2013-01-03
ATE532874T1 (de) 2011-11-15
AU2007221933A1 (en) 2007-11-01
DE60224383T2 (de) 2009-01-08
ATE382704T1 (de) 2008-01-15
US20060147902A1 (en) 2006-07-06
EP2319936A2 (de) 2011-05-11
US9518284B2 (en) 2016-12-13
EP1392849A2 (de) 2004-03-03
JP2004537973A (ja) 2004-12-24
WO2002065136A2 (en) 2002-08-22
AU2007221933B2 (en) 2010-12-16
EP2319936A3 (de) 2012-10-17
US20030073610A1 (en) 2003-04-17
AU2011200744A1 (en) 2011-03-17
US20110300533A1 (en) 2011-12-08
US20170306386A1 (en) 2017-10-26
WO2002065136A3 (en) 2003-12-11
CA2438661A1 (en) 2002-08-22
JP4344138B2 (ja) 2009-10-14
US20140273074A1 (en) 2014-09-18
EP1392849B1 (de) 2008-01-02
DE60224383T3 (de) 2012-06-28
CA2438661C (en) 2011-05-31
JP5152977B2 (ja) 2013-02-27
US20060141449A1 (en) 2006-06-29
AU2011200744B2 (en) 2013-04-04
US7045290B2 (en) 2006-05-16
AU2002250102B2 (en) 2007-07-12
EP1392849B2 (de) 2012-01-18
JP2008259509A (ja) 2008-10-30

Similar Documents

Publication Publication Date Title
DE60224383D1 (de) Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
ATE386942T1 (de) Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2007011834A3 (en) Compounds and method for the diagnosis and treatment of amyloid associated diseases
AU1618000A (en) Use of radioligands to screen inhibitors of amyloid-beta peptide production
AU4929701A (en) Whole-body optical imaging of gene expression and uses thereof
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
ATE462140T1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
DE60310668D1 (de) Tintensatz, Apparatur und Verfahren welche die Herstellung von Bildern mit reduzierter Glanzdifferenz ermöglichen
WO2006091964A3 (en) Regulators of protein misfolding and aggregation and methods of using the same
ATE323539T1 (de) Chromatographie-verfahren und vorrichtung welche einen konzentrations-schritt integrieren
WO2005108599A3 (en) Compositions and methods for treatment of protein misfolding diseases
ATE347698T1 (de) Verfahren zum nachweis von alzheimer-krankheit
EP1793001A3 (de) Verfahren zum Nachweis in Hefe für mittels die Proteinfaltung beeinflussen
WO2006134128A3 (en) Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
ATE312914T1 (de) Rdgb-proteine
WO2003087408A3 (en) Schizophrenia associated genes
WO2003093442A3 (en) Cell cultures from animal models of alzheimer's disease for screening and testing drug efficacy
WO2005038463A8 (en) Method for the detection of a neurological or psychiatric, demential disease, especially alzheimer's disease by use of cholecystokinin (cck) -molecules, corresponding substances and detection reagents
ATE458834T1 (de) Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
WO2004074245A3 (en) Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof
WO2004063226A3 (en) Novel fibrillin-like polypeptides
WO1999006838A3 (en) Novel method of detecting amyloid-like fibrils or protein aggregates

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN

R102 Epo decision maintaining patent in amended form now final

Ref document number: 1392849

Country of ref document: EP